ASH 2017: Highlights on Chronic Lymphocytic Leukaemia

Speaker: Christian Buske

Reporting from ASH 2017 on Chronic Lymphocytic Leukaemia, Christian Buske discusses studies investigating chemo-free approaches aiming to achieve MRD negativity and/or stopping treatment.  Increased MRD negativity was shown in MURANO with venetoclax+rituximab vs bendamustine+rituximab and in CLARITY with ibrutinib+venetoclax.

The phase III MURANO trial randomised patients with relapsed/refractory CLL to either venetoclax+rituximab vs bendamustine+rituximab. In the VR arm there was >80% risk reduction for PFS and >50% risk reduction for death: this represents a new treatment option for these patients. The CLARITY trial included ~50 patients with relapsed/refractory CLL and >30% MRD negativity was reported at 8 months. These data are encouraging and, in the future, could lead to stopping treatment once MRD negativity is achieved.


Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study
Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy